摘要 |
The invention includes bispecific molecules capable of cross-linking ITAM and ITIM receptors on a cell in order to inhibit cell activation, as well as gene therapy approaches using nucleotides encoding such bispecific molecules for expression in vivo. One example of an ITAM/ITIM receptor pair is FcepsilonRI and HM 18 , and another is FcepsilonRI and FcgammaRII. Cross-linking of these receptors with a bispecific molecule of the invention would lead to inhibition of the release of allergic mediators and amelioration of the symptoms of allergic diseases.
|